Last10K.com

Ovid Therapeutics Inc. (OVID) SEC Filing 8-K Material Event for the period ending Thursday, October 25, 2018

Ovid Therapeutics Inc.

HISTORY TOOLS
CIK: 1636651 Ticker: OVID

View differences made from one to another to evaluate Ovid Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ovid Therapeutics Inc..

Continue

Assess how Ovid Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ovid Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Ovid Therapeutics Inc. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Exhibit 99.2: Additional Exhibits
Ticker: OVID
CIK: 1636651
Form Type: 8-K Corporate News
Accession Number: 0001564590-18-025039
Submitted to the SEC: Thu Oct 25 2018 10:25:40 AM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Thursday, October 25, 2018
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ovid/0001564590-18-025039.htm